Dr Frank Lin
Dr Frank Lin is a medical oncologist and a biomedical informatician at the Garvan Institute of Medical Research. He completed his undergraduate medical training in New Zealand in 2003 (University of Otago). After his internship year, he undertook doctoral studies in biomedical informatics at the University of New South Wales, using informatics to study virulence factors of clinically relevant bacterial pathogens. He then commenced physician training in both New Zealand (Waikato Hospital) and Australia (St Vincent’s Hospital, Sydney), specialising in medical oncology.
The broad theme of his research is in the study of computational strategies to address complex information needs faced by oncologists, patients, and researchers alike. He is particularly interested in translating clinical and genomic data to deliver precision care in the oncology clinics. Some of his works, in the areas of machine learning-based decision support, electronic medical record (EMR) analysis, and clinical text mining, have been recognised previously.
He has developed several open-source software projects for EMR-based clinical research, including a text mining pipeline for knowledge discovery from the EMR and a specialised ontology for profiling treatment outcomes of cancer patients from EMR. He is an editorial board member of JCO Clinical Cancer Informatics.
He also maintains an open-source decision-support tool for guiding evidence-based recommendations of treatment and clinical trials based on cancer molecular biomarkers.
- 2001Summer Research Scholarship (University of Otago)
- 2005Australian Postgraduate Award (UNSW)
- 2011Best Research Poster Award (Bioinformatics & Computational Biology Conference - Singapore)
- 2016Best Trainee Research Poster Award (Medical Oncology Group of Australia ASM - Gold Coast)
- 2016John Shine Translational Research Fellowship (SVHS/Garvan)
- 2017Best Paper: Contributions from the 2016 Literature on Clinical Decision Support (IMIA)
- 2017RACP Trainee Research Award of Excellence
- 2018ANZUP/AstraZeneca Travel Fellowship
- 2018Waikato Medical Research Foundation Research Grant
- 2019ASCO Breakthrough Abstract Award
- 2023British journal of cancer10.1038/s41416-023-02311-0
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
- 2023Journal of the American Academy of Dermatology10.1016/j.jaad.2023.03.062
Response to Felmingham C. et al's "Improving Skin cancer Management with ARTificial intelligence (SMARTI): A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting".
- 2022Molecular oncology10.1002/1878-0261.13349
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.
The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey.